Study Stopped
No subject accrual
Factors Affecting Perioperative Outcomes
Factors Affectign Perioperative Outcomes After Surgery for Pelvic Organ Prolapse
1 other identifier
observational
N/A
1 country
1
Brief Summary
The specific aim of this study is to determine if pre-existing depression and anxiety affect perioperative outcomes measures patients undergoing surgery for pelvic organ prolapse.
- Hypothesis 1: Patients with depression will have increased analgesic use and longer hospital stays postoperatively
- Hypothesis 2: Patients with anxiety will have increased analgesic use and longer hospital stays postoperatively. A secondary aim is to characterize the incidence and severity of depression and anxiety in patients scheduled to undergo surgery for pelvic organ prolapse.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Sep 2011
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2011
CompletedFirst Submitted
Initial submission to the registry
January 19, 2012
CompletedFirst Posted
Study publicly available on registry
February 9, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2013
CompletedOctober 16, 2013
October 1, 2013
1.8 years
January 19, 2012
October 15, 2013
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Perioperative complications
1 week
Analgesic use
1 week
Length of hospital stay
1 week
Study Arms (2)
Abdominal
\- Participants undergoing surgeries with an abdominal approach will be given a Morphine PCA at a dose of 2mg every 10 minutes with a 12mg/hour lockout. They will also be given IV Toradol at 30mg every 6 hours as needed for a maximum of four doses.
Vaginal
\- Participants undergoing surgeries with a vaginal approach will be given hydrocodone/acetaminophen at a dose of 5/325 (1-2 tablets every four hours as needed), and provided with Ibuprofen 800mg every 8 hours as needed.
Eligibility Criteria
Participants will be drawn from the University of Oklahoma Urogynecology clinics. Our catchment area includes OU Physicians clinic (private clinic) and Presbyterian Professional Building (resident clinic).
You may qualify if:
- Age at least 21
- Scheduled to undergo surgery for the treatment of pelvic organ prolapse at the University of Oklahoma Health Sciences Center
You may not qualify if:
- Age \< 21
- Inability to complete the written questionnaires
- Undergoing concurrent procedures for condition other than pelvic organ prolapse
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Mikio Nihira, MD
University of Oklahoma
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 19, 2012
First Posted
February 9, 2012
Study Start
September 1, 2011
Primary Completion
June 1, 2013
Study Completion
June 1, 2013
Last Updated
October 16, 2013
Record last verified: 2013-10